United States · FDA National Drug Code directory

VENLAFAXINE HYDROCHLORIDE

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
10135-826_3d59e057-318b-f098-e063-6394a90a25be
Product NDC
10135-826
Form
CAPSULE, EXTENDED RELEASE
Composition / generic term
VENLAFAXINE HYDROCHLORIDE
Labeler
Marlex Pharmaceuticals, Inc.
Marketing category
ANDA
Marketing start / end (source format)
20250801
Source listing expiry
20261231

Source-listed ingredients

  • VENLAFAXINE HYDROCHLORIDE — 75 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10135-826-10) · 10135-826-10
  • 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10135-826-30) · 10135-826-30
  • 15 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10135-826-75) · 10135-826-75
  • 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10135-826-90) · 10135-826-90

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →